Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.46 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27228653 | 0.95 | DRD4 (0.48) | DPP7DRD4POLBSIGMAR1DRD2 | |
| SCHEMBL27228648 | 0.95 | DRD4 (0.48) | DPP7DRD4POLBSIGMAR1DRD2 | |
| SCHEMBL27232294 | 0.95 | DRD4 (0.48) | DPP7DRD4POLBSIGMAR1DRD2 | |
| SCHEMBL27228659 | 0.91 | SIGMAR1 (0.52) | DPP7DRD4SIGMAR1DRD2DRD3 | |
| SCHEMBL27228293 | 0.91 | SIGMAR1 (0.51) | DRD4SIGMAR1SLC6A12DCUN1D1 | |
| SCHEMBL31016690 | 0.91 | SIGMAR1 (0.51) | DRD4SIGMAR1SLC6A12DCUN1D1 | |
| SCHEMBL27228349 | 0.91 | PRKAA2 (0.51) | SIGMAR1DRD3SLC6A12 | |
| SCHEMBL31016658 | 0.89 | SIGMAR1 (0.52) | POLBSIGMAR1KMT2ADCUN1D1 | |
| SCHEMBL27228675 | 0.89 | SIGMAR1 (0.52) | POLBSIGMAR1KMT2ADCUN1D1 | |
| SCHEMBL27228579 | 0.88 | PRKAA2 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-05-30 | — | — | US | disclosed |
| EP-4305029-A1 | NEW 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022189392-A1 | NEW 2,3-DIHYDRO-1H-PYRROLO[3,2-b]PYRIDINE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | SIGMAR1, OPRD1, TMEM97 | DPP7 2525/4885DRD4 158/4885POLB 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.